Table 1.
Brief information of stimuli-responsive nanocarriers that is discussed in this review.
| Stimuli | Specific Conditions | Nanocarriers | Diagnostic /Imaging | Therapeutics | Reference |
|---|---|---|---|---|---|
| Light | Near-infrared (NIR) light | Gold nanocage@manganese dioxide (AuNC@MnO2) nanoparticles | √ | √ | Lee et al., 2019 |
| Titania-coated gold nanobipyramids | √ | Chen et al., 2019 | |||
| Poly(l-lysine)-conjugated chlorin e6 (Ce6) derivative nanoparticle | √ | Zhang et al., 2020 | |||
| Palladium nanosheet (PdNS) | √ | Wang et al., 2018 | |||
| Semiconducting polymer nanoadjuvant (SPNIIIR) | √ | Li et al., 2021 | |||
| CE7Q/CQ/S | √ | √ | Li et al., 2020 | ||
| Short-wavelength and NIR light | O-nitrobenzyl ester modified polymersome with up-conversion nanoparticles | √ | Tsai et al., 2021 | ||
| Ultrasound | Mechanical effect | Perfluoropentane containing nanobubbles | √ | Baspinar et al., 2019 | |
| Chemical effect | PEGylated Co2Fe2O4 nanoflowers (CFP) | √ | √ | Fu et al., 2021 | |
| Synergistically therapeutic modality | Cerasomal perfluorocarbon nanodroplet (D-vPCs-O2) | √ | √ | Ma et al., 2020 | |
| EXO-DVDMS | √ | √ | Liu et al., 2019 | ||
| Liposome-based nanobubbles | √ | √ | Lee et al., 2017; | ||
| pH | pH 5.7–6.9 | CHEMS-based liposomes; HA-ERL/BEV-LPH nanoparticles; DOX-loaded mixed micelles; DA-TAT carrier; mPEG-PHis-PSD; U11-DOX/CUR nanoparticles; Cis-aconitic anhydride-modified doxorubicin |
√ | Park et al., 2021; Pang et al., 2020; Shih et al., 2020; Jing et al., 2018; Shi et al., 2018; Hong et al., 2019; Xia et al., 2018 | |
| Enzyme | MMP-2 | Cur-P-NPs | √ | Han et al., 2017 | |
| MMP-9 | MMP-9-sensitive nanocarrier | √ | Sidi et al., 2019 | ||
| MMPs | A smart inhalable nanocarrier | √ | Vaghasiya et al., 2021 | ||
| HAase | HPGBCA | √ | Ren et al., 2019 | ||
| Esterase | Gold nanorod–curcumin conjugate, HAPBA | √ | Zhu et al., 2018; Lee et al., 2019 | ||
| NQO1 | QPA-P | √ | Park et al., 2021 |
√ Nanocarriers that designed for diagnostic/therapeutic applications.